(Q41545052)

3 October 2017

1 reference

title

The polycystic ovary syndrome. Pathogenesis, metabolic implications, and therapeutic approach (English)

1 reference

polycystic ovary syndrome

3 October 2017

main subject

1 reference

1 reference

Evanthia Diamanti-Kandarakis

series ordinal

1

object named as

Diamanti-Kandarakis E

1 reference

3 October 2017

language of work or name

English

0 references

publication date

1 June 1997

1 reference

Annals of the New York Academy of Sciences

3 October 2017

published in

1 reference

3 October 2017

volume

816

1 reference

3 October 2017

page(s)

177-193

1 reference

Polycystic ovaries--a common finding in normal women

3 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

Acute modulation of the hypothalamic-pituitary axis by intravenous testosterone in normal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

Polycystic ovary syndrome: interaction of follicle stimulating hormone and polypeptide growth factors in oestradiol production by human granulosa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

Testosterone and Androstenedione Blood Production Rates in Normal Women and Women with Idiopathic Hirsutism or Polycystic Ovaries*

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

Defects in beta-cell function in functional ovarian hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

Cellular mechanisms of insulin resistance in polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

Induction of insulin resistance by androgens and estrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1749-6632.1997.TB52142.X

10.1111/J.1749-6632.1997.TB52142.X

21 January 2018

Identifiers

DOI

1 reference

3 October 2017

1 reference